APMD Stock — Apnimed, Inc. Common Stock

Apnimed, Inc. Common Stock (APMD)

Updated October 16, 2026.

APMD is a Stock. Total return is 11.0% over the past 0.2 years, 6.1 points ahead of SPY at 4.9%.

Apnimed, Inc. is a clinical pharmaceutical company that develops and manufactures novel oral therapies for sleep-related breathing diseases, with a focus on AD109, an oral treatment designed to address obstructive sleep apnea by targeting underlying neuromuscular dysfunction. The company does not currently distribute dividends. Apnimed may appeal to investors seeking exposure to early-stage pharmaceutical development in the sleep medicine space, though it carries the risks inherent to clinical-stage companies without established revenue streams.

APMD performance versus SPY

Price and return data through 2026-10-16.

Total return is 11.0% over the past 0.2 years, 6.1 points ahead of SPY at 4.9%.

APMD key facts

Asset type

Stock

Asset class

Equity

Inception date

07/29/2026

Distribution frequency

None

Last close

$17.76 (as of 2026-10-16)

Market cap

$739,362,635

Average volume

235053.0

Payout ratio

0.0%

P/E ratio

2.46

EPS

$7.22

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider APMD — and who may not

It is a weaker fit for investors who need monthly cash flow (APMD does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on APMD

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions